在报名TIDES Europe时选择“Post-Event Meeting”作为附加选项，便可以参加会后研讨会：“OSI Europe”（11 月 6 日举行）。
详情请洽询 Global Information Co.， Ltd.（环球资讯有限企业）。

Exploring clinical updates from leading GLP-1, dual, and triple agonist programs across peptide and small molecule modalities, including efficacy data and novel oral formulations addressing limitations of injectable therapies.

Exploring RNA-based approaches for obesity, including siRNA-mediated inhibition of metabolic targets and non-coding RNA technologies with insights from Phase 1 clinical data.

Navigating regulatory pathways, reimbursement frameworks, and market access challenges to successfully translate innovative obesity therapeutics into commercially viable solutions across diverse European healthcare systems.

Examining valuation trends, licensing opportunities, and strategic collaborations shaping the obesity therapeutics landscape, with insights from leading investors, pharma BD&L teams, and emerging biotech innovators.

Integrating digital health solutions with obesity therapeutics to enhance patient engagement, treatment adherence, and real-world outcomes through connected technologies and data-driven personalization.

Connect with pharmaceutical executives, biotech innovators, clinical researchers, and investors during structured networking breaks designed to foster collaboration, exchange insights, and build strategic partnerships across the obesity innovation ecosystem.